A New Form of Specific Targeting Cancer Immunotherapy Using Anti‐tumor Monoclonal Antibody‐conjugated Lymphokine‐activated Killer Cells

Cross‐linking of effector T cells to target cancer cells augments their tumor lytic activities. Here we describe a new method of conjugating lymphokine‐activated killer (LAK) cells with cancer‐specific monoclonal antibody. The LAK cells were biotinylated, treated with avidin, and conjugated with bio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Jpn J Cancer Res
Main Authors: Shiraiwa, Hiroshi, Sekine, Teruaki, Tobisu, Ken‐ichi, Kakizoe, Tadao, Koiso, Kenkichi
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 1991
Assuntos:
Rapid Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5918496/
https://ncbi.nlm.nih.gov/pubmed/1906847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.1991.tb01895.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados